Aurélie Grandvuillemin
Business France(FR)
Publications by Year
Research Areas
Pharmacovigilance and Adverse Drug Reactions, Drug-Induced Adverse Reactions, COVID-19 Clinical Research Studies, Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Heparin-Induced Thrombocytopenia and Thrombosis
Most-Cited Works
- → Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort(2018)63 cited
- → Idarubicin‐loaded beads for chemoembolisation of hepatocellular carcinoma: results of theIDASPHEREphase I trial(2014)60 cited
- → Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database(2020)56 cited
- → Pulmonary hypertension associated with ponatinib therapy(2016)56 cited
- → Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study(2021)55 cited
- → Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009–2013 French PharmacoVigilance assessment(2014)30 cited
- → Tramadol and hypoglycaemia: comparison with other step 2 analgesic drugs(2012)30 cited
- → Atypical thrombosis associated with VaxZevria® (AstraZeneca) vaccine: Data from the French Network of Regional Pharmacovigilance Centres(2021)29 cited
- → Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell's palsy(2021)27 cited
- → French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge(2021)27 cited